Invex Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Invex Therapeutics's estimated annual revenue is currently $1.1M per year.
- Invex Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Invex Therapeutics has 7 Employees.
- Invex Therapeutics grew their employee count by -22% last year.
Invex Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Scientific Officer, Previous Executive Director, Founder | Reveal Email/Phone |
2 | Senior Clinical Trials Manager | Reveal Email/Phone |
3 | Clinical Trial Manager | Reveal Email/Phone |
Invex Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 48 | -21% | $16M | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 5 | -17% | N/A | N/A |
What Is Invex Therapeutics?
Invex Therapeutics (ASX: IXC) is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendinâ„¢.
keywords:N/A
N/A
Total Funding
7
Number of Employees
$1.1M
Revenue (est)
-22%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Subiaco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.6M | 8 | -20% | N/A |
#2 | $1.4M | 10 | -47% | N/A |
#3 | $3.5M | 14 | 17% | N/A |
#4 | $1.8M | 22 | 10% | N/A |
#5 | $4.3M | 25 | -7% | N/A |